Antibody reactivity to HIV-1 Vpu in HIV-1/AIDS patients on highly active antiretroviral therapy

Yi Ming A. Chen, Wei Yu Rey, Yu Ching Lan, Shu Fen Lai, Yu Chuan Huang, Shiow Ing Wu, Tze Tze Liu, Kwang Jen Hsiao

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Human immunodeficiency virus type 1 (HIV-1) Vpu protein promotes both extracellular release of viral particles and degradation of CD4 in the endoplasmic reticulum. The correlation of anti-Vpu antibody (Ab) reactivity to Vpu and AIDS disease progression was studied in 162 HIV-1/AIDS patients after they had received highly active antiretroviral therapy (HAART) for 1 year. Anti-Vpu Ab reactivity was analyzed by Western blot using a recombinant Vpu protein. Results showed that at baseline (prior to initiation of HAART), 31.5% of patients (51/162) had anti-Vpu Ab. The proportion of anti-Vpu Ab in patients with CD4 counts ≥500, 200-500 and <200/mm3 were 40.6, 34.7 and 14.3%, respectively (χ2 test, p < 0.05). In addition, decreasing levels of anti-Vpu Ab reactivity were significantly correlated with increasing levels of HIV-1 viral load. After receiving HAART for 1 year, 7 of 111 anti-Vpu Ab-negative patients (6.3%) seroconverted (-→+ group) and 8 of 51 anti-Vpu Ab-positive (15.7%) patients became negative (+→- group). Among 104 anti-Vpu Ab-negative patients, 40 were selected for analysis of the vpu gene. All of them had an intact vpu gene. Patients were further divided into four groups according to their anti-Vpu Ab serostatus and anti-HIV-1 Ab was measured. The results showed that only the anti-Vpu Ab serocon-verted group (-→+) had increased serum levels of anti-HIV-1 Abs after 1 year of HAART, while the other three groups (+→+, -→- and +→-) had decreased serum levels of anti-HIV-1 Abs after 1 year of HAART (p < 0.05). In conclusion, the presence of anti-Vpu Ab is associated with improved prognosis following HIV-1 infection, and seroconversion of anti-Vpu Ab in patients on HAART indicates significant recovery of immunity.

Original languageEnglish
Pages (from-to)266-275
Number of pages10
JournalJournal of Biomedical Science
Volume10
Issue number2
DOIs
Publication statusPublished - Mar 20 2003
Externally publishedYes

Fingerprint

Highly Active Antiretroviral Therapy
Viruses
HIV-1
Anti-Idiotypic Antibodies
Acquired Immunodeficiency Syndrome
Antibodies
vpu Genes
Genes
Recombinant proteins
Virus Diseases
CD4 Lymphocyte Count
Viral Load
Serum
Recombinant Proteins
Endoplasmic Reticulum
Virion
Disease Progression
Immunity
Western Blotting

Keywords

  • AIDS
  • Anti-Vpu antibody
  • Disease progression
  • Highly active antiretroviral therapy
  • IgG subclasses
  • Total IgG
  • Viral load
  • vpu gene

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Molecular Biology
  • Clinical Biochemistry
  • Cell Biology
  • Biochemistry, medical
  • Pharmacology (medical)

Cite this

Antibody reactivity to HIV-1 Vpu in HIV-1/AIDS patients on highly active antiretroviral therapy. / Chen, Yi Ming A.; Rey, Wei Yu; Lan, Yu Ching; Lai, Shu Fen; Huang, Yu Chuan; Wu, Shiow Ing; Liu, Tze Tze; Hsiao, Kwang Jen.

In: Journal of Biomedical Science, Vol. 10, No. 2, 20.03.2003, p. 266-275.

Research output: Contribution to journalArticle

Chen, Yi Ming A. ; Rey, Wei Yu ; Lan, Yu Ching ; Lai, Shu Fen ; Huang, Yu Chuan ; Wu, Shiow Ing ; Liu, Tze Tze ; Hsiao, Kwang Jen. / Antibody reactivity to HIV-1 Vpu in HIV-1/AIDS patients on highly active antiretroviral therapy. In: Journal of Biomedical Science. 2003 ; Vol. 10, No. 2. pp. 266-275.
@article{855008d655124d3fbd309dbe957a7247,
title = "Antibody reactivity to HIV-1 Vpu in HIV-1/AIDS patients on highly active antiretroviral therapy",
abstract = "Human immunodeficiency virus type 1 (HIV-1) Vpu protein promotes both extracellular release of viral particles and degradation of CD4 in the endoplasmic reticulum. The correlation of anti-Vpu antibody (Ab) reactivity to Vpu and AIDS disease progression was studied in 162 HIV-1/AIDS patients after they had received highly active antiretroviral therapy (HAART) for 1 year. Anti-Vpu Ab reactivity was analyzed by Western blot using a recombinant Vpu protein. Results showed that at baseline (prior to initiation of HAART), 31.5{\%} of patients (51/162) had anti-Vpu Ab. The proportion of anti-Vpu Ab in patients with CD4 counts ≥500, 200-500 and <200/mm3 were 40.6, 34.7 and 14.3{\%}, respectively (χ2 test, p < 0.05). In addition, decreasing levels of anti-Vpu Ab reactivity were significantly correlated with increasing levels of HIV-1 viral load. After receiving HAART for 1 year, 7 of 111 anti-Vpu Ab-negative patients (6.3{\%}) seroconverted (-→+ group) and 8 of 51 anti-Vpu Ab-positive (15.7{\%}) patients became negative (+→- group). Among 104 anti-Vpu Ab-negative patients, 40 were selected for analysis of the vpu gene. All of them had an intact vpu gene. Patients were further divided into four groups according to their anti-Vpu Ab serostatus and anti-HIV-1 Ab was measured. The results showed that only the anti-Vpu Ab serocon-verted group (-→+) had increased serum levels of anti-HIV-1 Abs after 1 year of HAART, while the other three groups (+→+, -→- and +→-) had decreased serum levels of anti-HIV-1 Abs after 1 year of HAART (p < 0.05). In conclusion, the presence of anti-Vpu Ab is associated with improved prognosis following HIV-1 infection, and seroconversion of anti-Vpu Ab in patients on HAART indicates significant recovery of immunity.",
keywords = "AIDS, Anti-Vpu antibody, Disease progression, Highly active antiretroviral therapy, IgG subclasses, Total IgG, Viral load, vpu gene",
author = "Chen, {Yi Ming A.} and Rey, {Wei Yu} and Lan, {Yu Ching} and Lai, {Shu Fen} and Huang, {Yu Chuan} and Wu, {Shiow Ing} and Liu, {Tze Tze} and Hsiao, {Kwang Jen}",
year = "2003",
month = "3",
day = "20",
doi = "10.1159/000068705",
language = "English",
volume = "10",
pages = "266--275",
journal = "Journal of Biomedical Science",
issn = "1021-7770",
publisher = "BioMed Central",
number = "2",

}

TY - JOUR

T1 - Antibody reactivity to HIV-1 Vpu in HIV-1/AIDS patients on highly active antiretroviral therapy

AU - Chen, Yi Ming A.

AU - Rey, Wei Yu

AU - Lan, Yu Ching

AU - Lai, Shu Fen

AU - Huang, Yu Chuan

AU - Wu, Shiow Ing

AU - Liu, Tze Tze

AU - Hsiao, Kwang Jen

PY - 2003/3/20

Y1 - 2003/3/20

N2 - Human immunodeficiency virus type 1 (HIV-1) Vpu protein promotes both extracellular release of viral particles and degradation of CD4 in the endoplasmic reticulum. The correlation of anti-Vpu antibody (Ab) reactivity to Vpu and AIDS disease progression was studied in 162 HIV-1/AIDS patients after they had received highly active antiretroviral therapy (HAART) for 1 year. Anti-Vpu Ab reactivity was analyzed by Western blot using a recombinant Vpu protein. Results showed that at baseline (prior to initiation of HAART), 31.5% of patients (51/162) had anti-Vpu Ab. The proportion of anti-Vpu Ab in patients with CD4 counts ≥500, 200-500 and <200/mm3 were 40.6, 34.7 and 14.3%, respectively (χ2 test, p < 0.05). In addition, decreasing levels of anti-Vpu Ab reactivity were significantly correlated with increasing levels of HIV-1 viral load. After receiving HAART for 1 year, 7 of 111 anti-Vpu Ab-negative patients (6.3%) seroconverted (-→+ group) and 8 of 51 anti-Vpu Ab-positive (15.7%) patients became negative (+→- group). Among 104 anti-Vpu Ab-negative patients, 40 were selected for analysis of the vpu gene. All of them had an intact vpu gene. Patients were further divided into four groups according to their anti-Vpu Ab serostatus and anti-HIV-1 Ab was measured. The results showed that only the anti-Vpu Ab serocon-verted group (-→+) had increased serum levels of anti-HIV-1 Abs after 1 year of HAART, while the other three groups (+→+, -→- and +→-) had decreased serum levels of anti-HIV-1 Abs after 1 year of HAART (p < 0.05). In conclusion, the presence of anti-Vpu Ab is associated with improved prognosis following HIV-1 infection, and seroconversion of anti-Vpu Ab in patients on HAART indicates significant recovery of immunity.

AB - Human immunodeficiency virus type 1 (HIV-1) Vpu protein promotes both extracellular release of viral particles and degradation of CD4 in the endoplasmic reticulum. The correlation of anti-Vpu antibody (Ab) reactivity to Vpu and AIDS disease progression was studied in 162 HIV-1/AIDS patients after they had received highly active antiretroviral therapy (HAART) for 1 year. Anti-Vpu Ab reactivity was analyzed by Western blot using a recombinant Vpu protein. Results showed that at baseline (prior to initiation of HAART), 31.5% of patients (51/162) had anti-Vpu Ab. The proportion of anti-Vpu Ab in patients with CD4 counts ≥500, 200-500 and <200/mm3 were 40.6, 34.7 and 14.3%, respectively (χ2 test, p < 0.05). In addition, decreasing levels of anti-Vpu Ab reactivity were significantly correlated with increasing levels of HIV-1 viral load. After receiving HAART for 1 year, 7 of 111 anti-Vpu Ab-negative patients (6.3%) seroconverted (-→+ group) and 8 of 51 anti-Vpu Ab-positive (15.7%) patients became negative (+→- group). Among 104 anti-Vpu Ab-negative patients, 40 were selected for analysis of the vpu gene. All of them had an intact vpu gene. Patients were further divided into four groups according to their anti-Vpu Ab serostatus and anti-HIV-1 Ab was measured. The results showed that only the anti-Vpu Ab serocon-verted group (-→+) had increased serum levels of anti-HIV-1 Abs after 1 year of HAART, while the other three groups (+→+, -→- and +→-) had decreased serum levels of anti-HIV-1 Abs after 1 year of HAART (p < 0.05). In conclusion, the presence of anti-Vpu Ab is associated with improved prognosis following HIV-1 infection, and seroconversion of anti-Vpu Ab in patients on HAART indicates significant recovery of immunity.

KW - AIDS

KW - Anti-Vpu antibody

KW - Disease progression

KW - Highly active antiretroviral therapy

KW - IgG subclasses

KW - Total IgG

KW - Viral load

KW - vpu gene

UR - http://www.scopus.com/inward/record.url?scp=0037217419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037217419&partnerID=8YFLogxK

U2 - 10.1159/000068705

DO - 10.1159/000068705

M3 - Article

C2 - 12595763

AN - SCOPUS:0037217419

VL - 10

SP - 266

EP - 275

JO - Journal of Biomedical Science

JF - Journal of Biomedical Science

SN - 1021-7770

IS - 2

ER -